|
Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC). |
|
|
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc. |
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc. |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |
|
|
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; Progenics; progenics; Sanofi |
Expert Testimony - Celgene; sanofi |
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi |
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Dendreon; Janssen; MTG Therapeutics; profound; Sanofi; Tokai Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Valeant Pharmaceuticals International |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Valeant Pharmaceuticals International |
|
|
|
Stock and Other Ownership Interests - Valeant Pharmaceuticals International |
|
|
|
Stock and Other Ownership Interests - Valeant Pharmaceuticals International |
|
|
|
Stock and Other Ownership Interests - Valeant Pharmaceuticals International |
|
|
Research Funding - Janssen (Inst) |